1. |
|
|
2. |
|
|
3. |
|
|
4. |
|
|
5. |
|
|
6. |
- Bergh, Jonas, et al.
(author)
-
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer : A randomised trial
- 2000
-
In: The Lancet. - 0140-6736 .- 1474-547X. ; 356:9239, s. 1384-1391
-
Journal article (peer-reviewed)abstract
- Background: Chemotherapy drug distribution varies greatly among individual patients. Therefore, we developed an individualised fluorouracil, epirubicin, cyclophosphamide (FEC) regimen to improve outcomes in patients with high-risk early breast cancer. We then did a randomised trial to compare this individually tailored FEC regimen with conventional adjuvant chemotherapy followed by consolidation with high-dose chemotherapy with stem-cell support. Methods: 525 women younger than 60 years of age with high-risk primary breast cancer were randomised after surgery to receive nine cycles of tailored FEC to haematological equitoxicity with granulocyte colony-stimulating factor (G-CSF) support (n=251), or three cycles of FEC at standard doses followed by high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin (CTCb), and peripheral-blood stem-cell or bone-marrow support (n=274). Both groups received locoregional radiation therapy and tamoxifen for 5 years. The primary outcome measure was relapse-free survival, and analysis was by intention to treat. Findings: At a median follow-up of 34.3 months, there were 81 breast-cancer relapses in the tailored FEC group versus 113 in the CTCb group (double triangular method p=0.04). 60 deaths occurred in the tailored FEC group and 82 in the CTCb group (log-rank p=0.12). Patients in the CTCb group experienced more grade 3 or 4 acute toxicity compared with the tailored FEC group (p<0.0001). Two treatment-related deaths (0.7%) occurred in the CTCb group. Six patients in the tailored FEC group developed acute myeloid leukaemia and three developed myelodysplastic syndrome. Interpretation: Tailored FEC with G-CSF support resulted in a significantly improved relapse-free survival and fewer grade 3 and 4 toxicities compared with marrow-supported high-dose chemotherapy with CTCb as adjuvant therapy of women with high-risk primary breast cancer.
|
|
7. |
- Nilsson Jannesson, Erik B, 1979-
(author)
-
Strategi, styrning och konkurrenskraft : En longitudinell studie av Saab AB
- 2010
-
Doctoral thesis (other academic/artistic)abstract
- Att skapa sammanhängande koncern-, affärs- och funktionsstrategier (strategisk kongruens), samt ett styrsystem med ett samstämmigt informationsflöde i och mellan de centrala styrverktygen (integrerad styrning), har sedan länge hävdats vara centralt för koncerners konkurrenskraft. I den mängd empiriska studier som legat till grund för detta har främst en eller två organisatoriska nivåer fokuserats när relationerna mellan strategier, styrning och konkurrenskraft diskuterats. Studier som tar ett helhetsgrepp om dessa samband efterfrågas därför för att öka kunskapen om och förståelsen av sambanden. Föreliggande avhandling svarar mot den efterfrågan.En longitudinell fallstudie för perioden 1995–2007 har genomförts. Strategier, ekonomistyrning och produktionsstyrning på koncern-, affärs- och funktionsnivå har studerats inom försvars- och säkerhetskoncernen Saab AB. Tre affärsenheter har studerats i detalj: Saab Aerosystems, Saab Bofors Dynamics och Saab Systems. Det empiriska materialet har samlats in genom 74 intervjuer med totalt 54 respondenter samt via både internt och publikt skriftligt material.Avhandlingen visar att strategisk kongruens och integrerad styrning skapas genom ömsesidig anpassning av strategier och styrning på koncern-, affärs- och funktionsnivå. Genom en sådan ömsesidighet anpassas styrningen till koncernens kritiska framgångsfaktorer och ett integrerat informationsflöde skapas. Inom Saab har detta i sin tur påverkat beteendet på alla nivåer och bidragit till att det förändrats i enlighet med strategierna. De senare har därmed implementerats. Samtidigt som dessa beteendeförändringar skett har Saabs konkurrenskraft varit god. Då implementerade strategier, anpassade utifrån omgivningen, kan antas vara en viktig del i ett företags framgång har Saabs strategiska kongruens och integrerade styrning rimligen haft en väsentlig betydelse för koncernens konkurrenskraft.
|
|
8. |
-
- 2019
-
Journal article (peer-reviewed)
|
|
9. |
- Abelev, Betty, et al.
(author)
-
Measurement of prompt J/psi and beauty hadron production cross sections at mid-rapidity in pp collisions at root s=7 TeV
- 2012
-
In: Journal of High Energy Physics. - 1029-8479. ; :11
-
Journal article (peer-reviewed)abstract
- The ALICE experiment at the LHC has studied J/psi production at mid-rapidity in pp collisions at root s = 7 TeV through its electron pair decay on a data sample corresponding to an integrated luminosity L-int = 5.6 nb(-1). The fraction of J/psi from the decay of long-lived beauty hadrons was determined for J/psi candidates with transverse momentum p(t) > 1,3 GeV/c and rapidity vertical bar y vertical bar < 0.9. The cross section for prompt J/psi mesons, i.e. directly produced J/psi and prompt decays of heavier charmonium states such as the psi(2S) and chi(c) resonances, is sigma(prompt J/psi) (p(t) > 1.3 GeV/c, vertical bar y vertical bar < 0.9) = 8.3 +/- 0.8(stat.) +/- 1.1 (syst.)(-1.4)(+1.5) (syst. pol.) mu b. The cross section for the production of b-hadrons decaying to J/psi with p(t) > 1.3 GeV/c and vertical bar y vertical bar < 0.9 is a sigma(J/psi <- hB) (p(t) > 1.3 GeV/c, vertical bar y vertical bar < 0.9) = 1.46 +/- 0.38 (stat.)(-0.32)(+0.26) (syst.) mu b. The results are compared to QCD model predictions. The shape of the p(t) and y distributions of b-quarks predicted by perturbative QCD model calculations are used to extrapolate the measured cross section to derive the b (b) over bar pair total cross section and d sigma/dy at mid-rapidity.
|
|
10. |
|
|